Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - nci_ncicdr0000062843-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Childhood Ependymoma Treatment
Childhood Brain Stem Glioma Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Pituitary Tumors Treatment
Standard Treatment Options for Recurrent Pituitary TumorsStandard treatment options for recurrent pituitary tumors include the following:Radiation therapy for postsurgical recurrence, which offers a high likelihood of local control.[1,2]Reirradiation, which provides long-term local control and control of visual symptoms.The question and selection of further treatment for patients who relapse is dependent on many factors, including the specific type of pituitary tumor, prior treatment, visual and hormonal complications, and individual patient considerations. Treatment Options Under Clinical Evaluation for Recurrent Pituitary TumorsTreatment options under clinical evaluation for recurrent pituitary tumors include the following:Stereotactic radiation surgery.[4,5,6]Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent pituitary tumor. The list of clinical trials can be further narrowed by
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (08 / 28 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Images were added to this summary and editorial changes were made.
Childhood Brain Stem Glioma Treatment (PDQ®): Treatment - Patient Information [NCI] - Thyrotropin-Producing Tumors Treatment
Standard Treatment Options for Thyrotropin-Producing TumorsStandard treatment options for thyrotropin-producing tumors include the following:Surgery (usually a transsphenoidal approach), with or without adjuvant radiation therapy.[1,2] Somatostatin analogues, such as octreotide.[3,4]Transsphenoidal surgery is the treatment of choice for patients with thyrotropic adenomas. Adjuvant radiation therapy may be employed when surgery is known to be noncurative even if the patient is still euthyroid because relapse is inevitable, and the full effect of radiation therapy requires months or years. Medical therapy may be required for patients who still have hyperthyroid symptoms despite surgery and external radiation. Somatostatin analogues are the drugs of choice for treatment; however, the efficacy of treatment may wane with time.[1,2,3,4]Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with pituitary tumor. The
Important It is possible that the main title of the report Meningioma is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...
Childhood Brain Stem Glioma Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Childhood Astrocytomas
The PDQ childhood brain tumor treatment summaries are organized primarily according to the World Health Organization (WHO) classification of nervous system tumors.[1,2] For a full description of the classification of nervous system tumors and a link to the corresponding treatment summary for each type of brain tumor, refer to the PDQ summary on Childhood Brain and Spinal Cord Tumors Treatment Overview.Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2002, childhood cancer mortality decreased by more than 50%. Childhood and adolescent cancer survivors require close follow-up because cancer therapy side effects may persist or develop months or years after treatment. Refer to the PDQ summary on Late Effects of Treatment for Childhood Cancer for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors.Primary brain tumors are a diverse group of
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (02 / 28 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. General Information About Adult Brain TumorsRevised text on factors used to diagnose brain metastases to include diagnostic procedures, including contrast magnetic resonance imaging (MRI) of the brain.Treatment Option OverviewAdded text to state that external-beam radiation therapy using either 3-dimensional conformal radiation therapy or intensity-modulated radiation therapy is considered an acceptable technique in radiation therapy delivery. Typically 2- to 3-cm margins on the MRI-based volumes to create the planning target volume are used. Dose escalation using radiosurgery has not improved outcomes.Added Souhami et al. as reference 15.Added Leptomeningeal carcinomatosis as a new subsection.Added text to state that a phase III randomized trial compared adjuvant whole-brain radiation therapy
Important It is possible that the main title of the report Astrocytoma, Malignant is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - Cellular Classification of Neuroblastic Tumors
Neuroblastomas are classified as one of the small, round, blue cell tumors of childhood. They are a heterogenous group of tumors composed of cellular aggregates with different degrees of differentiation, from mature ganglioneuromas to less mature ganglioneuroblastomas to immature neuroblastomas, reflecting the varying malignant potential of these tumors.There are two cellular classification systems for neuroblastoma.International Neuroblastoma Pathology Classification (INPC) System: The INPC system involves evaluation of tumor specimens obtained before therapy for the following morphologic features:[2,3,4,5]Amount of Schwannian stroma.Degree of neuroblastic maturation.Mitosis-karyorrhexis index of the neuroblastic cells.Favorable and unfavorable prognoses are defined on the basis of these histologic parameters and patient age. The prognostic significance of this classification system, and of related systems using similar criteria, has
Childhood Brain Stem Glioma Treatment (PDQ®): Treatment - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support